Skip to content
value.today

Pulmatrix, Inc.

🇺🇸 Lexington, Massachusetts, USAPharmaceuticalsFounded 2013

Pulmatrix, Inc. is listed today as Pulmatrix, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Pulmatrix, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$1 MPrivate placement after listingUnder $2 million

Pulmatrix, Inc.: Private sale, Mar 2026

Investors in this round

1 investor had bought by the notice of Apr 15, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Ludlum · Executive Officer · Interim CEO; Interim CFO
  • Anand Varadan · Director
  • Christopher Cabell · Director
  • Michael Higgins · Director
  • Richard Batycky · Director
  • Todd Bazemore · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The issuer issued 1,000 shares of Series B Convertible Preferred Stock, stated value $1,000 per share for aggregate proceeds of $1,000,000 in a private placement pursuant to Rule 506(b) of Regulation D.”
  • On a merger: “In connection with the signing of the Merger Agreement with Eos SENOLYTIX, Inc.”

Signed by Peter Ludlum, Interim CEO, Interim CFO. Source: SEC Form D, newest notice filed Apr 15, 2026. Read the notice at the SEC.

equitySEC
Apr 2020$8 MPrivate placement after listing$2 to $10 million

Pulmatrix, Inc.: Private sale, Apr 2020

Investors in this round

3 investors had bought by the notice of Apr 24, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$560,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michelle S. Siegert · Executive Officer, Director · Vice President of Finance
  • Teofilo Raad · Executive Officer, Director · Chief Executive Officer and Director
  • Amit D. Munshi · Director
  • Mark J. Iwicki · Director
  • Michael J. Higgins · Director · Chairman of Board of Directors
  • Richard D. Batycky · Director
  • Steven Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “H.C. Wainwright & Co., LLC received the above sales commission and the warrants in connection with the private placement and a concurrent registered direct offering by the Issuer, which is not reported on this Form D.”
  • On the amounts: “Represents warrants to investors to purchase up to 4,787,553 common shares at $1.55/share and warrants to H.C. Wainwright & Co., LLC to purchase up to 311,191 common shares at $2.0888/share, in connection with a 4/16/20 registered direct offering.”

Signed by Teofilo Raad, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Apr 24, 2020. Read the notice at the SEC.

optionsSEC
Feb 2019$2 MPrivate placement after listing$2 to $10 million

Pulmatrix, Inc.: Private sale, Feb 2019

Investors in this round

7 investors had bought by the notice of Feb 14, 2019: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Roach · Executive Officer · Chief Medical Officer
  • Robert Clarke · Executive Officer, Director · Chief Executive Officer, President and Director
  • Teofilo Raad · Executive Officer · Chief Business Officer
  • William Duke · Executive Officer · Chief Financial Officer, Treasurer and Secretary
  • Amit Munshi · Director
  • Mark Iwicki · Director
  • Matthew Sherman · Director
  • Michael Higgins · Director
  • Steven Gillis · Director
  • Terrance McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “H.C. Wainwright & Co., LLC received the above sales commission and the warrants in connection with the private placement and a concurrent registered direct offering by the Issuer, which is not reported on this Form D.”
  • On the amounts: “Includes warrants to purchase up to 1,706,484 shares of common stock at an exercise price of $1.34/share, issued to certain investors, and up to 110,922 shares of common stock at an exercise price of $1.8313/share, issued to H.C. Wainwright & Co., LLC.”

Signed by William Duke, Jr., Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Feb 14, 2019. Read the notice at the SEC.

optionsSEC
Dec 2018$4 MPrivate placement after listing$2 to $10 million

Pulmatrix, Inc.: Private sale, Dec 2018

Investors in this round

1 investor had bought by the notice of Dec 18, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Roach · Executive Officer · Chief Medical Officer
  • Robert Clarke · Executive Officer, Director · Chief Executive Officer, President and Director
  • Teofilo Raad · Executive Officer · Chief Business Officer
  • William Duke · Executive Officer · Chief Financial Officer, Treasurer and Secretary
  • Amit Munshi · Director
  • Mark Iwicki · Director
  • Matthew Sherman · Director
  • Michael Higgins · Director
  • Steven Gillis · Director
  • Terrance McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents the issuance of common warrants to purchase an aggregate of 9,375,000 shares of common stock at an exercise price of $0.39 per share.”

Signed by William Duke, Jr., Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Dec 18, 2018. Read the notice at the SEC.

optionsSEC
Jun 2015$21 MPrivate placement after listing$10 to $50 million

Pulmatrix, Inc.: Private sale, Jun 2015

Investors in this round

12 investors had bought by the notice of Jun 30, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $45 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Hava · Executive Officer · Chief Scientific Officer
  • Hojabr Alimi · Executive Officer, Promoter · Former Chief Executive Officer
  • Robert Clarke · Executive Officer, Director · Chief Executive Officer and Member of the Board of Directors
  • Sameer Harish · Executive Officer, Promoter · Former Chief Financial Officer
  • William Duke · Executive Officer · Chief Financial Officer, Treasurer and Secretary
  • David Maki · Director
  • Gregory French · Director, Promoter · Former Member of the Board of Directors
  • Kurt Graves · Director
  • Michael Higgins · Director
  • Richard Conley · Director, Promoter · Former Member of the Board of Directors
  • Scott Rocklage · Director
  • Steven Gillis · Director
  • Terrance McGuire · Director
  • Oculus Innovative Sciences, Inc. · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount includes (i) $21,383,416, representing shares that were issued in the merger and (ii) $24,084,696, representing the total aggregate exercise price of warrants issued in the merger.”
  • On a merger: “The offering was made in connection with a merger between Pulmatrix Operating Company, Inc. and Pulmatrix, Inc. A portion of the offering was cross-conditioned with the closing of the merger.”

Signed by William Duke, Jr., Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Jun 30, 2015. Read the notice at the SEC.

equity, optionsSEC
Jun 2015$3 MPrivate placement after listing$2 to $10 million

Pulmatrix, Inc.: Private sale, Jun 2015

Investors in this round

34 investors had bought by the notice of Jun 16, 2015: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$4,950
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$208,662
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hojabr Alimi · Executive Officer
  • Sameer Harish · Executive Officer
  • Akihisa Akao · Director
  • Gregory French · Director
  • Richard Conley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Dawson James Securities Inc. (CRD 130645) · Boca Raton, FloridaSold in AK, CA, CT, FL, IN, MA, MD, MN, NJ, NV, NY

Remarks in the notice

  • On fees: “Does not include a 1% non-accountable expense allowance”
  • On the amounts: “Offering is closed.”

Signed by Hojabr Alimi, Ceo. Source: SEC Form D, newest notice filed Jun 16, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pulmatrix, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2026).

    SEC Form D · Apr 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2026

That is all the official record says: Pulmatrix, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Pulmatrix, Inc. are on record.

Investors#

No investor of Pulmatrix, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Pulmatrix, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pulmatrix, Inc.
NameRoleNamed in
Peter LudlumInterim CEO; Interim CFOApr 2026
Michelle S. SiegertVice President of FinanceApr 2020
Teofilo RaadChief Executive Officer and DirectorApr 2020
James RoachChief Medical OfficerFeb 2019
Robert ClarkeChief Executive Officer, President and DirectorFeb 2019
William DukeChief Financial Officer, Treasurer and SecretaryFeb 2019
David HavaChief Scientific OfficerJun 2015
Hojabr AlimiFormer Chief Executive OfficerJun 2015
Sameer HarishFormer Chief Financial OfficerJun 2015
Anand VaradanDirectorApr 2026
Christopher CabellDirectorApr 2026
Michael HigginsDirectorApr 2026
Richard BatyckyDirectorApr 2026
Todd BazemoreDirectorApr 2026
Amit D. MunshiDirectorApr 2020
Mark J. IwickiDirectorApr 2020
Michael J. HigginsChairman of Board of DirectorsApr 2020
Michelle S. SiegertVice President of FinanceApr 2020
Richard D. BatyckyDirectorApr 2020
Steven GillisDirectorApr 2020
Teofilo RaadChief Executive Officer and DirectorApr 2020
Amit MunshiDirectorFeb 2019
Mark IwickiDirectorFeb 2019
Matthew ShermanDirectorFeb 2019
Robert ClarkeChief Executive Officer, President and DirectorFeb 2019
Terrance McGuireDirectorFeb 2019
David MakiDirectorJun 2015
Gregory FrenchFormer Member of the Board of DirectorsJun 2015
Kurt GravesDirectorJun 2015
Richard ConleyFormer Member of the Board of DirectorsJun 2015
Scott RocklageDirectorJun 2015
Akihisa AkaoDirectorJun 2015
Gregory FrenchFormer Member of the Board of DirectorsJun 2015
Hojabr AlimiFormer Chief Executive OfficerJun 2015
Oculus Innovative Sciences, Inc.PromoterJun 2015
Richard ConleyFormer Member of the Board of DirectorsJun 2015
Sameer HarishFormer Chief Financial OfficerJun 2015

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.